Bladder and erectile dysfunctions in the type 2 diabetic goto-kakizaki rat

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 306, Issue 2, 2014, Pages 108-117

  Oger Roussel, Stephanie ^a,b   Behr Roussel, Delphine ^a,b   Caisey, Stephanie ^a,b   Kergoat, Micheline ^c   Charon, Christine ^c   Audet, Annick ^c   Bernabé, Jacques ^a,b   Alexandre, Laurent ^e   Giuliano, Francois ^b,d  

^a Pelvipharm ^*  (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c Metabrain Research   (France)

^d RAYMOND POINCARÉ HOSPITAL   (France)

^e DNAVISION   (Belgium)

Author keywords

An timuscarinic; Phosphodiesterase type 5 inhibitor; Sexual dysfunction; Urology

Indexed keywords

SILDENAFIL; SOLIFENACIN;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CAPACITY; BLADDER CONTRACTION; BLADDER DYSFUNCTION; BLADDER FUNCTION; CONTROLLED STUDY; CYSTOMETRY; ELECTROSTIMULATION; ERECTILE DYSFUNCTION; GOTO KAKIZAKI RAT; MALE; MICTURITION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; WISTAR RAT;

ANTIMUSCARINIC; PHOSPHODIESTERASE TYPE 5 INHIBITOR; SEXUAL DYSFUNCTION; UROLOGY;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; ERECTILE DYSFUNCTION; MALE; PENILE ERECTION; PIPERAZINES; PURINES; QUINUCLIDINES; RATS; RATS, WISTAR; SULFONES; TETRAHYDROISOQUINOLINES; URINARY BLADDER; URINARY BLADDER DISEASES; URINATION; UROLOGICAL AGENTS; VASODILATOR AGENTS;

EID: 84892594671     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00033.2013     Document Type: Article

References (56)

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-commit- tee of the International Continence Society. Urology 61: 37-49, 2003.
2. Abrams P, Cardozo L, Wein A. 3rd International Consultation on Incontinence-Research Society 2011. Neurourol Urodyn 31: 291-292, 2012.
3. Aizawa N, Homma Y, Igawa Y. Characteristics of lower urinary tract dysfunction and bladder afferent nerve properties in type 2 diabetic goto-kakizaki rats. J Urol 189: 1580-1587, 2013.
4. Akash MS, Rehman K, Chen S. An overview of valuable scientific models for diabetes mellitus. Curr Diabetes Rev 9: 286-293, 2013.
5. Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor-which is the main mechanism of action? Eur Urol 43: 1-5, 2003.
6. Banerjee S, Banerjee PP, Brown TR. Castration-induced apoptotic cell death in the Brown Norway rat prostate decreases as a function of age. Endocrinology 141: 821-832, 2000.
7. Bansal R, Agarwal MM, Modi M, Mandal AK, Singh SK. Urodynamic profile of diabetic patients with lower urinary tract symptoms: association of diabetic cystopathy with autonomic and peripheral neuropathy. Urology 77: 699-705, 2011.
8. Behr-Roussel D, Gorny D, Mevel K, Caisey S, Bernabe J, Burgess G, Wayman C, Alexandre L, Giuliano F. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur Urol 47: 87-91, 2005.
9. Behr-Roussel D, Oger S, Pignol B, Pham E, Le MA, Chabrier PE, Caisey S, Compagnie S, Picaut P, Bernabe J, Alexandre L, Giuliano F, Denys P. Minimal effective dose of dysport and botox in a rat model of neurogenic detrusor overactivity. Eur Urol 61: 1054-1061, 2012.
10. Berthelier C, Kergoat M, Portha B. Lack of deterioration of insulin action with aging in the GK rat: a contrasted adaptation as compared with nondiabetic rats. Metabolism 46: 890-896, 1997.
11. Caremel R, Oger-Roussel S, Behr-Roussel D, Grise, Giuliano FA. Nitric oxide/cyclic guanosine monophosphate signalling mediates an in- hibitory action on sensory pathways of the micturition reflex in the rat. Eur Urol 58: 616-625, 2010.
12. Carneiro FS, Giachini FR, Carneiro ZN, Lima VV, Ergul A, Webb RC, Tostes RC. Erectile dysfunction in young non-obese type II diabetic Goto-Kakizaki rats is associated with decreased eNOS phosphorylation at Ser1177. J Sex Med 7: 3620-3634, 2010.
13. Cheng ZJ, Vaskonen T, Tikkanen I, Nurminen K, Ruskoaho H, Vapaatalo H, Muller D, Park JK, Luft FC, Mervaala EM. Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. Hypertension 37: 433-439, 2001.
14. Cho SY, Park K, Paick JS, Kim SW. Change of erectile function and responsiveness to phosphodiesterase type 5 inhibitors at different stages of streptozotocin-induced diabetes in rats. J Sex Med 8: 1352-1361, 2011.
15. Christ GJ, Hsieh Y, Zhao W, Schenk G, Venkateswarlu K, Wang HZ, Tar MT, Melman A. Effects of streptozotocin-induced diabetes on bladder and erectile (dys)function in the same rat in vivo. BJU Int 97: 1076-1082, 2006.
16. Corona G, Mannucci E, Mansani R, Petrone L, Bartolini M, Giommi R, Forti G, Maggi M. Organic, relational and psychological factors in erectile dysfunction in men with diabetes mellitus. Eur Urol 46: 222-228, 2004.
17. Daneshgari F, Huang X, Liu G, Bena J, Saffore L, Powell CT. Temporal differences in bladder dysfunction caused by diabetes, diuresis, and treated diabetes in mice. Am J Physiol Regul Integr Comp Physiol 290: R1728-R1735, 2006.
18. Daneshgari F, Liu G, Birder L, Hanna-Mitchell AT, Chacko S. Diabetic bladder dysfunction: current translational knowledge. J Urol 182: S18-S26, 2009.
19. Daneshgari F, Moore C. Diabetic uropathy. Semin Nephrol 26: 182-185, 2006.
20. Derosa G, Tinelli C, D'Angelo A, Ferrara G, Bonaventura A, Bianchi L, Romano D, Fogari E, Maffioli P. Glyco-metabolic profile among type 2 diabetic patients with erectile dysfunction. Endocr J 59: 611-619, 2012.
21. Desrois M, Clarke K, Lan C, Dalmasso C, Cole M, Portha B, Cozzone PJ, Bernard M. Upregulation of eNOS and unchanged energy metabo- lism in increased susceptibility of the aging type 2 diabetic GK rat heart to ischemic injury. Am J Physiol Heart Circ Physiol 299: H1679-H1686, 2010.
22. Fedele D. Therapy Insight: sexual and bladder dysfunction associated with diabetes mellitus. Nat Clin Pract Urol 2: 282-290, 2005.
23. Gasbarro G, Lin DL, Vurbic D, Quisno A, Kinley B, Daneshgari F, Damaser MS. Voiding function in obese and Type 2 diabetic female rats. Am J Physiol Renal Physiol 298: F72-F77, 2010.
24. Giuliano F, Bernabe J, Jardin A, Rousseau JP. Antierectile role of the sympathetic nervous system in rats. J Urol 150: 519-524, 1993.
25. Giuliano FA, Rampin O, Benoit G, Jardin A. Neural control of penile erection. Urol Clin North Am 22: 747-766, 1995.
26. Golbidi S, Laher I. Bladder dysfunction in diabetes mellitus. Front Pharmacol 1: 136, 2010.
27. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, Vardi, Wespes E. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 57: 804-814, 2010.
28. Hurt KJ, Musicki B, Palese MA, Crone JK, Becker RE, Moriarity JL, Snyder SH, Burnett AL. Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection. Proc Natl Acad Sci USA 99: 4061-4066, 2002.
29. Iltis I, Kober F, Desrois M, Dalmasso C, Lan C, Portha B, Cozzone PJ, Bernard M. Defective myocardial blood flow and altered function of the left ventricle in type 2 diabetic rats: a noninvasive in vivo study using perfusion and cine magnetic resonance imaging. Invest Radiol 40: 19-26, 2005.
30. Kaplan SA, Te AE, Blaivas JG. Urodynamic findings in patients with diabetic cystopathy. J Urol 153: 342-344, 1995.
31. Kempler P, Amarenco G, Freeman R, Frontoni S, Horowitz M, Stevens M, Low P, Pop-Busui R, Tahrani A, Tesfaye S, Varkonyi T, Ziegler D, Valensi P. Gastrointestinal autonomic neuropathy, erectile-, bladder- and sudomotor dysfunction in patients with diabetes mellitus: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev doi:10.1002/dmrr.1223. 2011.
32. Kendirci M, Tanriverdi O, Trost L, Hellstrom WJ. Management of sildenafil treatment failures. Curr Opin Urol 16: 449-459, 2006.
33. Kovanecz I, Ferrini MG, Vernet D, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Pioglitazone prevents corporal veno-occlusive dysfunction in a rat model of type 2 diabetes mellitus. BJU Int 98: 116-124, 2006.
34. Lewis RW, Fugl-Meyer KS, Corona G, Hayes RD, Laumann EO, Moreira ED, Jr, Rellini AH, Segraves T. Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med 7: 1598-1607, 2010.
35. Luttrell IP, Swee M, Starcher B, Parks WC, Chitaley K. Erectile dysfunction in the type II diabetic db/db mouse: impaired venoocclusion with altered cavernosal vasoreactivity and matrix. Am J Physiol Heart Circ Physiol 294: H2204-H2211, 2008.
36. Matsumoto Y, Torimoto K, Matsuyoshi H, Hirayama A, Fujimoto K, Yoshimura, Hirao Y. Long-term effects of diabetes mellitus on voiding function in a new model of type 2 diabetes mellitus, the Spontaneously Diabetic Torii (SDT) rat. Biomed Res (Tokyo) 30: 331-335, 2009.
37. Michel MC, Mehlburger L, Schumacher H, Bressel HU, Goepel M. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol 163: 1725-1729, 2000.
38. Movassat J, Bailbe D, Lubrano-Berthelier C, Picarel-Blanchot F, Bertin E, Mourot J, Portha B. Follow-up of GK rats during prediabetes highlights increased insulin action and fat deposition despite low insulin secretion. Am J Physiol Endocrinol Metab 294: E168-E175, 2008.
39. Oudot A, Behr-Roussel D, Poirier S, Sandner P, Bernabe J, Alexandre L, Giuliano F. Combination of BAY 60 - 4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure. Eur Urol 60: 1020-1026, 2011.
40. Porst, H, Gacci M, Büttner H, Henneges C, Boess F. Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-con- trolled, clinical studies. Eur Urol pii: S0302-S2838 (13)01024-5, 2013.
41. Portha B, Giroix MH, Tourrel-Cuzin C, Le-Stunff H, Movassat J. The GK rat: a prototype for the study of non-overweight Type 2 diabetes. Methods Mol Biol 933: 125-159, 2012.
42. Prins GS. Differential regulation of androgen receptors in the separate rat prostate lobes: androgen independent expression in the lateral lobe. J Steroid Biochem 33: 319-326, 1989.
43. Saito M, Okada S, Kazuyama E, Satoh I, Kinoshita Y, Satoh K. Pharmacological properties, functional alterations and gene expression of muscarinic receptors in young and old type 2 Goto-Kakizaki diabetic rat bladders. J Urol 180: 2701-2705, 2008.
44. Sarma AV, Burke JP, Jacobson DJ, McGree ME, St SJ, Girman CJ, Lieber MM, Herman W, Macoska J, Montie JE, Jacobsen SJ. Associations between diabetes and clinical markers of benign prostatic hyper- plasia among community-dwelling Black and White men. Diabetes Care 31: 476-482, 2008.
45. Sarma AV, St Sauver JL, Hollingsworth JM, Jacobson DJ, McGree ME, Dunn RL, Lieber MM, Jacobsen SJ. Diabetes treatment and progression of benign prostatic hyperplasia in community-dwelling black and white men. Urology 79: 102-108, 2012.
46. Schrijvers BF, De Vriese AS, Van D, V, Rasch R, Lameire NH, Flyvbjerg A. Long-term renal changes in the Goto-Kakizaki rat, a model of lean type 2 diabetes. Nephrol Dial Transplant 19: 1092-1097, 2004.
47. Sohn EJ, Kim CS, Kim YS, Jung DH, Jang DS, Lee YM, Kim JS. Effects of magnolol (5,5=-diallyl-2,2=-dihydroxybiphenyl) on diabetic ne- phropathy in type 2 diabetic Goto-Kakizaki rats. Life Sci 80: 468-475, 2007.
48. Suzuki T, Fujimoto N, Kitamura S, Ohta S. Quantitative determination of lobe specificity of mRNA expression of androgen-dependent genes in the rat prostate gland. Endocr J 54: 123-132, 2007.
49. Tanaka Y, Masumori N, Tsukamoto T. Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder. Int J Urol 17: 796-800, 2010.
50. Ueno N, Iwamoto Y, Segawa N, Kinoshita M, Ueda H, Katsuoka Y. The effect of sildenafil on electrostimulation-induced erection in the rat model. Int J Impot Res 14: 251-255, 2002.
51. Valensi P, Mesangeau D, Paries J, Zkhiri F, Garnier M. Erythrocyte rheology and heart hypertrophy in diabetes mellitus. J Mal Vasc 21: 185-187, 1996.
52. dp (Type II) rats with erectile dysfunction. Endocrinology 136: 5709-5717, 1995.
53. Wilson JD. The critical role of androgens in prostate development. Endocrinol Metab Clin North Am 40: 577-590, ix, 2011.
54. Wingard C, Fulton D, Husain S. Altered penile vascular reactivity and erection in the Zucker obese-diabetic rat. J Sex Med 4: 348-362, 2007.
55. Yono M, Latifpour J, Yoshida M, Ueda S. Age-related alterations in the biochemical and functional properties of the bladder in type 2 diabetic GK rats. J Recept Signal Transduct Res 25: 147-157, 2005.
56. Zhang XH, Filippi S, Morelli A, Vignozzi L, Luconi M, Donati S, Forti G, Maggi M. Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes. J Sex Med 3: 253-264, 2006.